Limits...
ERp19 contributes to tumorigenicity in human gastric cancer by promoting cell growth, migration and invasion.

Wu J, Chen XH, Wang XQ, Yu Y, Ren JM, Xiao Y, Zhou T, Li P, Xu CD - Oncotarget (2015)

Bottom Line: However, the role of ERp19 in gastric cancer (GC) remains undefined.Furthermore, ERp19 knockdown dramatically suppressed gastric cancer cell growth, inhibited cellular migration/invasion and down regulated the phosphorylation of FAK and paxillin, whereas ERp19 over-expression reversed these changes.ERp19 may represent a new diagnostic and prognostic marker and a novel target for the treatment of GC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic.

ABSTRACT
ERp19, a mammalian thioredoxin-like protein, plays a key role in defense against endoplasmic reticulum stress. It belongs to the protein disulfide isomerize (PDI) family, whose members have been implicated in development of breast, ovarian and gastrointestinal cancers. However, the role of ERp19 in gastric cancer (GC) remains undefined. Therefore, we sought to investigate the expression and prognostic value of ERp19 in GC patients, and to explore the role of ERp19 in tumorigenicity. Expression of ERp19 in gastric tissues was assessed by immunohistochemical staining and real-time PCR in clinical samples of GC patients. Statistical analysis of clinical cases revealed that the expression levels of ERp19 were higher in tumor tissues than non-tumor tissues. And the level of ERp19 expression was correlated with tumor size, lymph node involvement and poor clinical prognosis. Furthermore, ERp19 knockdown dramatically suppressed gastric cancer cell growth, inhibited cellular migration/invasion and down regulated the phosphorylation of FAK and paxillin, whereas ERp19 over-expression reversed these changes. We conclude that ERp19 contributes to tumorigenicity and metastasis of GC by activating the FAK signaling pathway, and may function as an oncogene in GC. ERp19 may represent a new diagnostic and prognostic marker and a novel target for the treatment of GC.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier survival curves in gastric carcinoma according to ERp19 stainingPatients with ERp19 strong staining had a significantly poorer prognosis than those with weak staining. P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494905&req=5

Figure 2: Kaplan-Meier survival curves in gastric carcinoma according to ERp19 stainingPatients with ERp19 strong staining had a significantly poorer prognosis than those with weak staining. P < 0.05.

Mentions: Association between ERp19 protein expression and clinicopathological characteristics of GC in 90 patients was shown in Table 1. Chi-square test suggested that high expression of ERp19 in GC was significantly correlated with tumor size (P=0.041) and lymph node involvement (P=0.034). However, there were no statistically significant relationships between ERp19 expression and other clinicopathological variables such as age, gender, histological grade, Lauren's classification or TNM stage. 5-year-follow-up of the 90 patients revealed that 61% (55 of 90) patients had died, with the median survival time of 27.5 months for patients with strong ERp19 staining and 52 months for those with weak staining. The Kaplan-Meier survival analysis indicated that the survival rate of patients with strong staining was significantly lower than that of those with weak staining (P < 0.05, Fig. 2). Together these results provide evidence that up-regulated ERp19 expression may be associated with GC malignancy.


ERp19 contributes to tumorigenicity in human gastric cancer by promoting cell growth, migration and invasion.

Wu J, Chen XH, Wang XQ, Yu Y, Ren JM, Xiao Y, Zhou T, Li P, Xu CD - Oncotarget (2015)

Kaplan-Meier survival curves in gastric carcinoma according to ERp19 stainingPatients with ERp19 strong staining had a significantly poorer prognosis than those with weak staining. P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494905&req=5

Figure 2: Kaplan-Meier survival curves in gastric carcinoma according to ERp19 stainingPatients with ERp19 strong staining had a significantly poorer prognosis than those with weak staining. P < 0.05.
Mentions: Association between ERp19 protein expression and clinicopathological characteristics of GC in 90 patients was shown in Table 1. Chi-square test suggested that high expression of ERp19 in GC was significantly correlated with tumor size (P=0.041) and lymph node involvement (P=0.034). However, there were no statistically significant relationships between ERp19 expression and other clinicopathological variables such as age, gender, histological grade, Lauren's classification or TNM stage. 5-year-follow-up of the 90 patients revealed that 61% (55 of 90) patients had died, with the median survival time of 27.5 months for patients with strong ERp19 staining and 52 months for those with weak staining. The Kaplan-Meier survival analysis indicated that the survival rate of patients with strong staining was significantly lower than that of those with weak staining (P < 0.05, Fig. 2). Together these results provide evidence that up-regulated ERp19 expression may be associated with GC malignancy.

Bottom Line: However, the role of ERp19 in gastric cancer (GC) remains undefined.Furthermore, ERp19 knockdown dramatically suppressed gastric cancer cell growth, inhibited cellular migration/invasion and down regulated the phosphorylation of FAK and paxillin, whereas ERp19 over-expression reversed these changes.ERp19 may represent a new diagnostic and prognostic marker and a novel target for the treatment of GC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic.

ABSTRACT
ERp19, a mammalian thioredoxin-like protein, plays a key role in defense against endoplasmic reticulum stress. It belongs to the protein disulfide isomerize (PDI) family, whose members have been implicated in development of breast, ovarian and gastrointestinal cancers. However, the role of ERp19 in gastric cancer (GC) remains undefined. Therefore, we sought to investigate the expression and prognostic value of ERp19 in GC patients, and to explore the role of ERp19 in tumorigenicity. Expression of ERp19 in gastric tissues was assessed by immunohistochemical staining and real-time PCR in clinical samples of GC patients. Statistical analysis of clinical cases revealed that the expression levels of ERp19 were higher in tumor tissues than non-tumor tissues. And the level of ERp19 expression was correlated with tumor size, lymph node involvement and poor clinical prognosis. Furthermore, ERp19 knockdown dramatically suppressed gastric cancer cell growth, inhibited cellular migration/invasion and down regulated the phosphorylation of FAK and paxillin, whereas ERp19 over-expression reversed these changes. We conclude that ERp19 contributes to tumorigenicity and metastasis of GC by activating the FAK signaling pathway, and may function as an oncogene in GC. ERp19 may represent a new diagnostic and prognostic marker and a novel target for the treatment of GC.

No MeSH data available.


Related in: MedlinePlus